Positive Phase III results for PEG-intron

Enzon (ENZN) partner Schering-Plough (SGP) reported results of a 1,219-patient Phase III trial showing that PEG-Intron pegylated interferon alfa-2b, which uses ENZN's polyethylene glycol (PEG) technology,

Read the full 263 word article

How to gain access

Continue reading with a
two-week free trial.